Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
NTRA Stock Overview
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide.
Natera Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$37.53 |
52 Week High | US$129.09 |
52 Week Low | US$26.10 |
Beta | 1.23 |
1 Month Change | -5.40% |
3 Month Change | -42.47% |
1 Year Change | -58.10% |
3 Year Change | 60.66% |
5 Year Change | 266.50% |
Change since IPO | 65.04% |
Recent News & Updates
Shareholder Returns
NTRA | US Biotechs | US Market | |
---|---|---|---|
7D | 4.5% | 0.4% | 1.0% |
1Y | -58.1% | -22.1% | -15.1% |
Return vs Industry: NTRA underperformed the US Biotechs industry which returned -22.1% over the past year.
Return vs Market: NTRA underperformed the US Market which returned -13.2% over the past year.
Price Volatility
NTRA volatility | |
---|---|
NTRA Average Weekly Movement | 17.5% |
Biotechs Industry Average Movement | 12.4% |
Market Average Movement | 7.8% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NTRA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: NTRA's weekly volatility has increased from 11% to 17% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 2,670 | Steve Chapman | https://www.natera.com |
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father.
Natera Fundamentals Summary
NTRA fundamental statistics | |
---|---|
Market Cap | US$3.61b |
Earnings (TTM) | -US$546.46m |
Revenue (TTM) | US$667.30m |
5.4x
P/S Ratio-6.6x
P/E RatioIs NTRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NTRA income statement (TTM) | |
---|---|
Revenue | US$667.30m |
Cost of Revenue | US$354.82m |
Gross Profit | US$312.48m |
Other Expenses | US$858.94m |
Earnings | -US$546.46m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -5.67 |
Gross Margin | 46.83% |
Net Profit Margin | -81.89% |
Debt/Equity Ratio | 61.0% |
How did NTRA perform over the long term?
See historical performance and comparisonValuation
Is Natera undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
6.66x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NTRA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NTRA's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: NTRA is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Biotechs industry average.
PE vs Market: NTRA is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NTRA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NTRA is overvalued based on its Price-To-Book Ratio (6.7x) compared to the US Biotechs industry average (1.4x).
Future Growth
How is Natera forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Future Growth Score
1/6Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
17.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NTRA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NTRA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NTRA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NTRA's revenue (18.3% per year) is forecast to grow faster than the US market (7.7% per year).
High Growth Revenue: NTRA's revenue (18.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NTRA is forecast to be unprofitable in 3 years.
Past Performance
How has Natera performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-31.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NTRA is currently unprofitable.
Growing Profit Margin: NTRA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NTRA is unprofitable, and losses have increased over the past 5 years at a rate of 31.3% per year.
Accelerating Growth: Unable to compare NTRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NTRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: NTRA has a negative Return on Equity (-100.76%), as it is currently unprofitable.
Financial Health
How is Natera's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NTRA's short term assets ($980.2M) exceed its short term liabilities ($231.1M).
Long Term Liabilities: NTRA's short term assets ($980.2M) exceed its long term liabilities ($371.3M).
Debt to Equity History and Analysis
Debt Level: NTRA has more cash than its total debt.
Reducing Debt: NTRA's debt to equity ratio has reduced from 67.8% to 61% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NTRA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NTRA has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 31.3% each year.
Dividend
What is Natera current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NTRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NTRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NTRA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NTRA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NTRA has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
3.3yrs
Average management tenure
CEO
Steve Chapman (42 yo)
3.33yrs
Tenure
US$23,343,147
Compensation
Mr. Steven Leonard Chapman, also known as Steve, has been Chief Executive Officer, President and Director at Natera, Inc. since January 02, 2019. Mr. Chapman served as Chief Operating Officer of Natera, In...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD23.34M) is above average for companies of similar size in the US market ($USD6.91M).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: NTRA's management team is considered experienced (3.3 years average tenure).
Board Members
Experienced Board: NTRA's board of directors are considered experienced (5.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NTRA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.9%.
Top Shareholders
Company Information
Natera, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Natera, Inc.
- Ticker: NTRA
- Exchange: NasdaqGS
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$3.615b
- Shares outstanding: 96.31m
- Website: https://www.natera.com
Number of Employees
Location
- Natera, Inc.
- 13011 McCallen Pass Building A
- Suite 100
- San Carlos
- California
- 78753
- United States
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/25 00:00 |
End of Day Share Price | 2022/05/25 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.